Loading...
XTSE
CPH
Market cap248mUSD
Jun 06, Last price  
13.25CAD
1D
8.08%
1Q
17.36%
Jan 2017
170.41%
IPO
413.57%
Name

Cipher Pharmaceuticals Inc

Chart & Performance

D1W1MN
XTSE:CPH chart
No data to show
P/E
21.48
P/S
7.43
EPS
0.45
Div Yield, %
Shrs. gr., 5y
-1.84%
Rev. gr., 5y
8.24%
Revenues
33m
+57.66%
646,633778,997543,2691,267,8713,036,0045,384,1383,495,5928,501,95525,367,9198,258,99534,409,00040,740,00040,320,00022,749,00022,451,00021,607,00021,943,00020,675,00021,162,00033,363,000
Net income
12m
-43.36%
0000055,99102,557,22023,448,25601,769,000-39,149,0004,403,000543,0003,242,0004,549,0007,758,00026,636,00020,383,00011,545,000
CFO
20m
+22.17%
000001,242,80106,898,6667,020,29507,764,00011,469,00019,930,00011,284,0008,860,00011,691,00013,814,00010,575,00015,999,00019,546,000
Earnings
Aug 06, 2025

Profile

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
IPO date
Feb 25, 2004
Employees
5
Domiciled in
CA
Incorporated in
CA

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
33,363
57.66%
21,162
2.36%
20,675
-5.78%
Cost of revenue
21,498
9,902
9,625
Unusual Expense (Income)
NOPBT
11,865
11,260
11,050
NOPBT Margin
35.56%
53.21%
53.45%
Operating Taxes
(8,590)
(7,702)
(15,157)
Tax Rate
NOPAT
20,455
18,962
26,207
Net income
11,545
-43.36%
20,383
-23.48%
26,636
243.34%
Dividends
Dividend yield
Proceeds from repurchase of equity
(176)
(5,559)
(1,988)
BB yield
0.05%
3.95%
0.48%
Debt
Debt current
283
94
101
Long-term debt
40,873
612
755
Deferred revenue
Other long-term liabilities
Net debt
23,319
(39,119)
(46,921)
Cash flow
Cash from operating activities
19,546
15,999
10,575
CAPEX
(44)
(21)
(81)
Cash from investing activities
(80,044)
(144)
(81)
Cash from financing activities
39,296
(5,244)
(1,914)
FCF
22,357
15,808
26,170
Balance
Cash
17,837
39,825
28,836
Long term investments
18,941
Excess cash
16,169
38,767
46,743
Stockholders' equity
95,818
74,765
58,722
Invested Capital
126,752
42,106
12,861
ROIC
24.23%
68.99%
428.37%
ROCE
8.30%
13.92%
18.54%
EV
Common stock shares outstanding
24,568
25,422
107,486
Price
14.32
158.48%
5.54
44.27%
3.84
116.95%
Market cap
351,820
149.80%
140,839
-65.88%
412,746
769.14%
EV
375,139
101,720
365,825
EBITDA
15,882
12,487
12,039
EV/EBITDA
23.62
8.15
30.39
Interest
464
Interest/NOPBT
4.20%